Thermo Fishr Sci - TMO STOCK NEWS

Thermo Fisher Scientific (NYSE: TMO) announced that its Olink® Explore Platform has been selected for the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The project aims to analyze over 5,400 proteins from 600,000 samples to discover new protein biomarkers for disease prediction, diagnosis, and treatment.

The project, a collaboration between UK Biobank and 14 leading biopharmaceutical companies, builds on a 2023 pilot project that analyzed 54,000 samples. The study is scheduled to begin in Q1 2025, with data releases starting in 2026 and full dataset availability in 2027. Initially, the project will analyze 300,000 samples, with plans to secure additional funding for another 300,000 samples.

The pilot study's research, published in Nature, has already been cited over 400 times, demonstrating its significant impact on understanding disease development and advancing targeted treatments. One study identified protein risk factors for certain cancers up to seven years before diagnosis.

Thermo Fisher Scientific (NYSE: TMO) has announced that Marc N. Casper, chairman, president and chief executive officer, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 11:15 a.m. (EST). Interested parties can access the webcast through the Investors section of Thermo Fisher's website at www.thermofisher.com.

Thermo Fisher Scientific (NYSE: TMO) has announced it will release its Q4 and full-year 2024 financial results before market opening on Thursday, January 30, 2025. The company will host a conference call at 8:30 a.m. EST to discuss financial performance and future expectations.

Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 internationally, using access code 706921. The call will also be available on the company's website investor section. A replay will be accessible through February 14, 2025, under the News, Events & Presentations section.

Thermo Fisher Scientific (NYSE: TMO) has announced the completion of a $1 billion share repurchase program, which resulted in the buyback of 1.9 million shares of its common stock. As of December 3, 2024, the company maintains $3 billion in remaining authorization for future share repurchases.

Thermo Fisher Scientific (NYSE: TMO) announced that its Board of Directors has authorized a new $4 billion share repurchase program. The program, which has no expiration date, will allow the company to buy back shares through open market or negotiated transactions. This new authorization replaces the existing program, which had $1 billion remaining.

Thermo Fisher Scientific (NYSE: TMO) has announced that their chairman, president and CEO Marc N. Casper will deliver a presentation at the Wolfe Healthcare Conference. The presentation is scheduled for Tuesday, November 19, 2024, at 8:00 a.m. EDT. Interested parties can watch the live webcast through the Investors section of Thermo Fisher's website.

Thermo Fisher Scientific (NYSE: TMO) has announced its Board of Directors has approved a quarterly cash dividend of $0.39 per common share. The dividend will be paid on January 15, 2025, to shareholders who are on record as of December 13, 2024.

Thermo Fisher Scientific (NYSE: TMO) reported Q3 2024 financial results with revenue of $10.60 billion, flat compared to $10.57 billion in Q3 2023. GAAP EPS was $4.25, down from $4.42, while adjusted EPS reached $5.28, compared to $5.69 in the prior year. The company's operating margin decreased to 17.3% from 17.6% year-over-year.

The quarter featured launches of innovative products, including the Iliad scanning transmission electron microscope and MagMAX Sequential DNA/RNA kit. Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07 and maintained revenue guidance of $42.4-$43.3 billion.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has announced its plans to release third quarter 2024 financial results before the market opens on Wednesday, October 23, 2024. The company will hold a conference call at 8:30 a.m. EDT on the same day to discuss its financial performance and future expectations.

Investors can participate in the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S., using the access code 296868. The call will also be available for live listening on the "Investors" section of Thermo Fisher's website. A replay of the call will be accessible under "News, Events & Presentations" until Wednesday, November 6, 2024.